Autoimmune Diseases / 2012 / Article / Tab 1

Clinical Study

Improved Metabolic Control in Diabetes, HSP60, and Proinflammatory Mediators

Table 1

Characteristics of patients enrolled in the study.

PatientAgeSexBMIHgbA1C (n.v. 6,6)HOMAWaist circum (cm)Diabetes treatment: drugs (+diet and physical activity)Lenght of treatment (years/months) Comorbidties

151M35348., DL
266M303015., DL
352F31317., DL
467F36357., DL, CVA
564M28247., DL
665F27.525., DL
767M31277., DL
860M31309., DL
974F37337. + Repaglinid1/2HTN, DL, Afib
1067F38348. + Glimepirid0/6HTN, DL
1150M292712. + Glimepirid0/6HTN, DL
1271F40388., DL
1371F43398., DL
1473F322986.94.53.8102102Metformin0/8HTN, DL
1559F41409.16.710.94.0121118Metformin1/5HTN, DL
1655F41398., DL
1747M31298., DL

Pat: patient; n.v: normal value; circum: circumference; treatment: Treatment; comorbidities: cardiovascular comorbidities; HTN: hypertension; DL: dyslipidemia; CVA: cerebral vascular accident; Afib: atrial fibrillation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.